Plantarc Bio Ltd (PLNT) - Total Assets
Based on the latest financial reports, Plantarc Bio Ltd (PLNT) holds total assets worth ILA8.39 Million ILA (≈ $22.50K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Plantarc Bio Ltd - Total Assets Trend (2018–2024)
This chart illustrates how Plantarc Bio Ltd's total assets have evolved over time, based on quarterly financial data. Also see PLNT stock market capitalisation for the company's overall valuation and market capitalisation.
Plantarc Bio Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Plantarc Bio Ltd's total assets of ILA8.39 Million consist of 95.4% current assets and 4.6% non-current assets. Review how much debt does Plantarc Bio Ltd carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 89.0% |
| Accounts Receivable | ILA602.00K | 5.5% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Plantarc Bio Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Plantarc Bio Ltd stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Plantarc Bio Ltd's current assets represent 95.4% of total assets in 2024, an increase from 79.2% in 2018.
- Cash Position: Cash and equivalents constituted 89.0% of total assets in 2024, up from 70.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 5.5% of total assets.
Plantarc Bio Ltd Competitors by Total Assets
Key competitors of Plantarc Bio Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ:NAMS
|
USA | $786.43 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Mesoblast Ltd
AU:MSB
|
Australia | AU$782.31 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
Plantarc Bio Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.51 | 9.59 | 4.00 |
| Quick Ratio | 10.51 | 9.59 | 4.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA7.20 Million | ILA10.07 Million | ILA1.68 Million |
Plantarc Bio Ltd - Advanced Valuation Insights
This section examines the relationship between Plantarc Bio Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | -17.0% |
| Total Assets | ILA10.94 Million |
| Market Capitalization | $1.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Plantarc Bio Ltd's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Plantarc Bio Ltd's assets decreased by 17.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Plantarc Bio Ltd (2018–2024)
The table below shows the annual total assets of Plantarc Bio Ltd from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA10.94 Million ≈ $29.33K |
-17.04% |
| 2023-12-31 | ILA13.19 Million ≈ $35.35K |
-13.41% |
| 2022-12-31 | ILA15.23 Million ≈ $40.83K |
-18.63% |
| 2021-12-31 | ILA18.71 Million ≈ $50.17K |
+768.04% |
| 2020-12-31 | ILA2.16 Million ≈ $5.78K |
-45.15% |
| 2019-12-31 | ILA3.93 Million ≈ $10.54K |
+83.78% |
| 2018-12-31 | ILA2.14 Million ≈ $5.73K |
-- |
About Plantarc Bio Ltd
PlantArc Bio Ltd. operates as an Ag-Bio company for the crop protection and yield enhancement. The company develops and operates a Direct-In-Plant gene discovery platform. It focuses on yield improvement, drought resistance, and herbicide and insects tolerance. The company was incorporated in 2014 and is based in Ra'anana, Israel.